News
RPHM
1.830
+5.17%
0.090
Reneo Pharmaceuticals, Inc. Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period Ended March 31, 2024
Press release · 1d ago
RPHM Stock Earnings: Reneo Pharmaceuticals Beats EPS for Q1 2024
Reneo Pharmaceuticals reported earnings per share of -25 cents for the first quarter of 2024. The company did not report any revenue for the quarter. This was above the analyst estimate for EPS of -29 cents. Reneo pharmaceuticals just reported results for first quarter.
Investorplace · 1d ago
BRIEF-Reneo Pharmaceuticals Q1 EPS USD -0.25
Reuters · 1d ago
RENEO PHARMACEUTICALS INC - RETAINED AN INDEPENDENT FINANCIAL ADVISOR TO INITIATE A FORMAL PROCESS TO EVALUATE POTENTIAL STRATEGIC ALTERNATIVES
Reuters · 1d ago
Press Release: Reneo Pharmaceuticals Reports -2-
Net cash used in operating activities includes cash flows from property and equipment purchases and investments. Dow Jones Newswires says the company has more than $100 million in cash and cash equivalents at the end of the period. The company expects to use the majority of the cash in the next 12 months to pay down debt.
Dow Jones · 1d ago
Weekly Report: what happened at RPHM last week (0429-0503)?
Weekly Report · 2d ago
Weekly Report: what happened at RPHM last week (0422-0426)?
Weekly Report · 04/29 09:50
Weekly Report: what happened at RPHM last week (0415-0419)?
Weekly Report · 04/22 09:47
Weekly Report: what happened at RPHM last week (0408-0412)?
Weekly Report · 04/15 09:43
Weekly Report: what happened at RPHM last week (0401-0405)?
Weekly Report · 04/08 09:45
Weekly Report: what happened at RPHM last week (0325-0329)?
Weekly Report · 04/01 09:45
Sell Rating on Reneo Pharmaceuticals Amid Strategic Uncertainty and Reduced Price Target
Analyst Jason Zemansky from Bank of America Securities reiterated a Sell rating on the stock and has a $1.20 price target. Reneo Pharmaceuticals (RPHM) has been revisited by a Wall Street analyst on March 28. The company’s future direction is uncertain after the failure of their main development program in December.
TipRanks · 03/31 14:35
Reneo Pharmaceuticals, Inc.: Securities to be offered to employees in employee benefit plans
Press release · 03/29 00:06
Reneo Pharmaceuticals GAAP EPS of -$2.52
Seeking Alpha · 03/28 19:13
RPHM Stock Earnings: Reneo Pharmaceuticals Misses EPS for Q4 2023
Reneo Pharmaceuticals reported earnings per share of -70 cents for the fourth quarter of 2023. The company did not report any revenue for the quarter. This was below the analyst estimate for EPS of -62 cents. Reneo pharmaceuticals just reported results.
Investorplace · 03/28 16:53
Reneo Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Reneo Pharmaceuticals Inc reports results for the quarter ended in December. The company reported a quarterly adjusted loss of 71 cents per share. The mean expectation of five analysts was for a loss of 58 cents. Reported revenue was zero; analysts expected zero; shares had risen by 3.1% this quarter.
Reuters · 03/28 12:49
Reneo Pharmaceuticals: Q4 Earnings Insights
Reneo Pharmaceuticals reported its Q4 earnings on March 28. The company missed estimates by 13.0% and missed by $0.7. Reneo pharmaceuticals is expected to announce its earnings Thursday morning. The firm's revenue was down $0 from the same period last year.
Benzinga · 03/28 12:00
Reneo Pharmaceuticals Q4 GAAP EPS $(0.70) Misses $(0.62) Estimate; Cash, Cash Equivalents, And Short-term Investments Of $103M
Benzinga · 03/28 11:37
*Reneo Pharmaceuticals 4Q Research and Development Expenses $17.6M >RPHM
Dow Jones · 03/28 11:36
BRIEF-Reneo Pharmaceuticals Q4 EPS USD -0.7
Reuters · 03/28 11:35
More
Webull provides a variety of real-time RPHM stock news. You can receive the latest news about Reneo Pharmaceuticals, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About RPHM
Reneo Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The Company's product candidate, mavodelpar, is a potent and selective agonist of the peroxisome proliferator-activated receptor delta (PPARd). Mavodelpar helps in increasing the transcription of genes involved in mitochondrial function and increases fatty acid oxidation (FAO) and may increase the production of new mitochondria. The Company is developing REN001 in the two rare genetic diseases that present with myopathy and have unmet medical needs: primary mitochondrial myopathies (PMM), and long-chain fatty acid oxidation disorders (LC-FAOD).